
    
      This is an open-label, Phase 2 study designed to assess the efficacy and safety of ibrutinib
      combined with rituximab in previously untreated subjects with FL.

      There are two study treatment arms.

      Subjects enrolled into main study treatment arm will receive ibrutinib continuously until
      disease progression or unacceptable toxicity. In addition, subjects will receive rituximab
      once weekly for four doses for the first four weeks of study treatment.

      Subjects enrolled into the exploratory study treatment arm will receive ibrutinib
      continuously as a single agent for the first eight weeks, then ibrutinib concurrently with
      rituximab once weekly for four doses. After the rituximab treatment, subjects will receive
      ibrutinib continuously until disease progression or unacceptable toxicity.
    
  